RLAY

Relay Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 7/10
  • Momentum↑ 9/10
Relay Therapeutics sales and earnings growth
RLAY Growth
Good
  • Revenue Y/Y↓ -16.49%
  • EPS Y/Y↑ 34.10%
  • FCF Y/Y↑ 11.93%
Relay Therapeutics gross and profit margin trends
RLAY Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -3561.40%
  • ROIC↓ -45.00%
Relay Therapeutics net debt vs free cash flow
RLAY Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Relay Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗